Omalizumab

Generic Details

Generic Name

Omalizumab

Other Names

  • Xolair

Drug Class

  • Monoclonal Antibody

Chemical Formula

C6402H9916N1716O2024S42

Molecular Weight

149000 Daltons

Mechanism of Action

  • Binds to immunoglobulin E (IgE) and prevents it from binding to its receptor, thereby reducing allergic response

Indications

  • Severe persistent asthma
  • Chronic idiopathic urticaria

Common Dosage Forms

  • Subcutaneous injection

Typical Dosage

  • 150-375 mg every 2-4 weeks, based on body weight and IgE levels

Pediatric Dosage

  • Dosing based on body weight and IgE levels

Geriatric Dosage

  • No specific dosage adjustments required

Side Effects

  • Injection site reactions
  • Headache
  • Fatigue
  • Joint pain
  • Upper respiratory tract infection

Contraindications

  • Hypersensitivity to omalizumab or any component of the formulation

Pregnancy Category

  • C - Risk cannot be ruled out

Lactation Safety

  • Limited data available, use with caution

Drug Interactions

  • No significant interactions reported

Overdose Symptoms

  • No specific overdose symptoms reported

Antidote for Overdose

  • No specific antidote, manage symptoms supportively

Storage Conditions

  • Refrigerate at 2-8°C (36-46°F), do not freeze

Pharmacokinetics

  • Absorption: Slow and steady subcutaneous absorption
  • Distribution: Binds to IgE in blood, distributed to tissues
  • Metabolism: Expected to be degraded into small peptides and amino acids
  • Excretion: Primarily through the reticuloendothelial system

Precautions

  • Monitor for anaphylaxis and hypersensitivity reactions during administration
  • Do not administer beyond recommended dose

Warnings

  • Risk of anaphylaxis immediately after administration
  • Do not use for acute bronchospasm or status asthmaticus

Others

  • Requires professional training for administration to ensure proper subcutaneous injection